Literature DB >> 7802762

Tetrahydrobiopterin synthesis and inducible nitric oxide production in pulmonary artery smooth muscle.

D K Nakayama1, D A Geller, M Di Silvio, G Bloomgarden, P Davies, B R Pitt, K Hatakeyama, H Kagamiyama, R L Simmons, T R Billiar.   

Abstract

We recently reported (Am. J. Respir. Cell Mol. Biol. 7: 471-476, 1992) that a mixture of lipopolysaccharide (LPS) and cytokines produced a time-dependent increase in mRNA and protein expression of inducible nitric oxide synthase (iNOS) in cultured rat pulmonary artery smooth muscle cells (RPASM). In the current study we extend observations on regulation of iNOS in RPASM by showing that de novo synthesis of tetrahydrobiopterin (BH4) is critical for LPS and cytokine-induced NO production. A mixture of LPS and the cytokines gamma-interferon, interleukin-1 beta, and tumor necrosis factor-alpha increased steady-state levels of mRNA of GTP-cyclohydrolase-I (GTP-CH), the rate-limiting enzyme in BH4 biosynthesis. Levels of mRNA to GTP-CH became detectable by 4 h, with further increases at 24 h by Northern blot analysis and reverse-transcriptase polymerase chain reaction. Total intracellular biopterin levels, undetectable under basal conditions, increased after 24 h exposure to LPS and cytokines (to 32.3 +/- 0.8 pmol/mg protein). LPS and cytokine-induced NO production, determined by nitrite concentrations in the medium, was decreased in a concentration-dependent manner by the GTP-CH inhibitor, 2,4-diamino-6-hydroxypyrimidine (DAHP) at 24 h. DAHP also inhibited completely the LPS- and cytokine-induced accumulation of intracellular biopterins. Sepiapterin, which supplies BH4 through a salvage pathway independent of GTP-CH, reversed the effect of DAHP on LPS and cytokine-induced NO production.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7802762     DOI: 10.1152/ajplung.1994.266.4.L455

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis.

Authors:  L L Shears; N Kawaharada; E Tzeng; T R Billiar; S C Watkins; I Kovesdi; A Lizonova; S M Pham
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

2.  Vascular gene transfer of the human inducible nitric oxide synthase: characterization of activity and effects on myointimal hyperplasia.

Authors:  E Tzeng; L L Shears; P D Robbins; B R Pitt; D A Geller; S C Watkins; R L Simmons; T R Billiar
Journal:  Mol Med       Date:  1996-03       Impact factor: 6.354

3.  Induction of L-arginine transport and nitric oxide synthase in vascular smooth muscle cells: synergistic actions of pro-inflammatory cytokines and bacterial lipopolysaccharide.

Authors:  S M Wileman; G E Mann; A R Baydoun
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

4.  Interleukin 1 beta and cAMP trigger the expression of GTP cyclohydrolase I in rat renal mesangial cells.

Authors:  C Plüss; E R Werner; N Blau; H Wachter; J Pfeilschifter
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

5.  GTP cyclohydrolase I expression, protein, and activity determine intracellular tetrahydrobiopterin levels, independent of GTP cyclohydrolase feedback regulatory protein expression.

Authors:  Amy L Tatham; Mark J Crabtree; Nicholas Warrick; Shijie Cai; Nicholas J Alp; Keith M Channon
Journal:  J Biol Chem       Date:  2009-03-13       Impact factor: 5.157

Review 6.  Nitric oxide. Novel biology with clinical relevance.

Authors:  T R Billiar
Journal:  Ann Surg       Date:  1995-04       Impact factor: 12.969

7.  Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy.

Authors:  Adriano R Tonelli; Sarah Haserodt; Metin Aytekin; Raed A Dweik
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.